SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                          -----------------------------

                                    FORM 8-K

                                 CURRENT REPORT

                     PURSUANT TO SECTION 13 OR 15(d) of the
                         SECURITIES EXCHANGE ACT OF 1934

                         ------------------------------


       Date of Report (Date of earliest event reported): February 7, 2001


                                   TCPI, INC.
                                   ----------
             (Exact name of registrant as specified in its charter)



       Florida                          0-25406               65-0308922
       -------                          --------              ----------
(State or other jurisdiction           (Commission           (I.R.S. Employer
 of incorporation)                      File Number)         Identification No.)


               3341 S.W. 15TH STREET
               POMPANO BEACH, FLORIDA                              33069
               -----------------------                             -----
           (Address of principal executive offices)              (Zip code)


        Registrant's telephone number, including area code: 954/979-0400


                                 Not Applicable
                                 --------------
          (Former name or former address, if changed since last report)





ITEM 5.   OTHER EVENTS

TCPI And The Americare Companies Settle Noninvasive Glucose Monitoring
- ----------------------------------------------------------------------
Patent Infringement Lawsuit And All Other Litigation Matters
- ------------------------------------------------------------

         On February 5, 2001,  the Company  announced the settlement of a patent
infringement lawsuit related to its noninvasive TD GLUCOSE(TM) MONITORING SYSTEM
as well as all other  litigation  between TCPI and Americare  Health Scan, Inc.,
its subsidiaries, affiliates and Joseph P. D'Angelo.

         The  parties  agreed  to  dismiss  the  various  lawsuits  and  related
counterclaims  and have entered into mutual  releases of all claims  relating to
the respective legal matters. Further, none of the parties admits any wrongdoing
related to claims in the various lawsuits and associated counterclaims. Terms of
the settlement agreement are not being disclosed at this time.

         Management   stated  that  the  termination  of  these  lawsuits  is  a
significant  event and brings  closure to legal  matters that have been going on
over the past three years. Further, management believes that ongoing development
of the Company's current noninvasive  glucose monitoring  technology can proceed
without  concern of future lawsuits from the Americare  companies.  In addition,
financial and management  resources will be freed up as to continue to implement
the Company's business plan.

Forward Looking Statements
- --------------------------

         Information in this Form 8-K, including any information incorporated by
reference herein,  includes  "forward-looking  statements" within the meaning of
Section 27A of the  Securities  Act of 1933, as amended,  and Section 21E of the
Securities Act of 1934, as amended, and is subject to the safe-harbor created by
such sections.  The Company's actual results may differ  significantly  from the
results discussed in such forward-looking statements.

         Statements regarding  development and FDA clearance of future products,
future  prospects,  business plans and  strategies,  future revenues and revenue
sources,  the  resolution of pending  litigation,  future  liquidity and capital
resources,  healthcare  market  directions,  future  acceptance of the Company's
products,  possible  recommendations of healthcare professionals or governmental
agencies  regarding use of diagnostic  products,  possible growth in markets for
at-home  diagnostic  testing,  the possibility  and timing of additional  equity
investments,  mergers,  acquisitions or other strategic transactions, as well as
other  statements  contained in this report that address  activities,  events or
developments that the Company expects, believes or anticipates will or may occur
in the future,  and similar  statements are  forward-looking  statements.  These
statements are based upon  assumptions and analyses made by the Company in light
of  current  conditions,  future  developments  and other  factors  the  Company
believes are  appropriate in the  circumstances,  or  information  obtained from
third  parties  and  are  subject  to  a  number  of   assumptions,   risks  and
uncertainties.  Readers are cautioned  that  forward-looking  statements are not
guarantees of future performance and that actual results might differ materially
from those  suggested or projected in the  forward-looking  statements.  Factors
that may cause actual future events to differ significantly from those predicted
or assumed  include,  but are not  limited  to:  the  satisfactory  conduct  and
completion of clinical trials  demonstrating  efficacy of the Company's products





including TD Glucose(TM)  Monitoring System and Total Cholesterol Home Screening
Test; FDA and foreign  regulatory  clearance of the TD Glucose Monitoring System
and Total Cholesterol Home Screening Test; delays in product development;  risks
associated  with the Company's  ability to  successfully  develop and market new
products on a profitable  basis or at all; the Company's  ability to finance and
complete  the  acquisition  of  certain  assets  of  Roche   Diagnostics   GmbH,
availability of labor and sufficient parts and materials to complete the design,
construction  and  manufacturing  scale-up  of  required  equipment;  ability to
complete the design,  construction and manufacturing  scale-up on a timely basis
within  budget  parameters;  receipt of any required  regulatory  approvals  for
manufacturing  equipment or related facilities;  future advances in technologies
and medicine; the uncertainties of healthcare reform; risks related to the early
stage of the Company's  existence and its products'  development;  the Company's
ability to execute its business plans;  engineering  development;  lead time for
delivery of equipment;  the Company's  dependence on outside parties such as its
key customers,  suppliers,  licensing and alliance  partners;  competition  from
major  pharmaceutical,  medical and diagnostic  companies;  risks and expense of
government  regulation  and effects of changes in  regulation  (including  risks
associated with obtaining requisite FDA and other governmental approvals for the
Company's products);  the limited experience of the Company in manufacturing and
marketing products;  uncertainties connected with product liability exposure and
insurance;   risks  associated  with  domestic  and  international   growth  and
expansion;  risks  associated  with  international  operations  (including  risk
associated with international  economies,  currencies and business  conditions);
risks associated with obtaining and maintaining patents and other protections of
intellectual  property;  risks  associated  with  uncertainty  of litigation and
appeals,  and the payment of judgments not reversed on appeal or otherwise;  the
Company's  limited  cash  reserves  and  sources  of  liquidity,  including  the
satisfaction of terms and conditions relating to funding, and timing and receipt
of proceeds from any funding;  uncertainties  regarding timing and effectiveness
of registration  statements;  uncertainties in availability of expansion capital
in the future and other risks associated with capital markets, including funding
of ongoing operations,  risks associated with the Company's ability to negotiate
and obtain additional financing, equity investments or strategic transactions on
favorable  terms or at all and the influence,  if any, a delay in developing the
Company's  products,  including  the TD  Glucose  Monitoring  System  and  Total
Cholesterol  Home  Screening Test may have on such funding of operations and for
obtaining additional financing, equity investments or strategic transactions, as
well as those  listed in the  Company's  other press  releases  and in its other
filings with the Securities and Exchange  Commission.  The Company may determine
to  discontinue  or delay the  development  of any or all of its products  under
development at any time.  Moreover,  the Company may not be able to successfully
develop  and market new  products,  complete  planned  acquisitions,  enter into
strategic  alliances or implement any or all of its operating strategy unless it
is able to generate  additional  liquidity and working  capital.  For a complete
description of the Company's business, products and liquidity, see the Company's
Annual Report on Form 10-K for the year ended  December 31, 1999 and  subsequent
quarterly reports on Form 10-Q.




                                   SIGNATURES

         Pursuant to the  requirements  of the Securities  Exchange Act of 1934,
the  Registrant  has duly  caused  this report to be signed on its behalf by the
undersigned, thereunto duly authorized.

Dated: February 7, 2001        TCPI, INC.



                               By:  /s/ Walter V. Usinowicz, Jr.
                                   ----------------------------------
                                   Walter V. Usinowicz, Jr.
                                   Vice President of Finance and Chief
                                   Financial Officer (Chief Accounting Officer)